Nasus Pharma Doses First Patient in NS002 Phase 2 Study
Ticker: NSRX · Form: 6-K · Filed: Nov 18, 2025 · CIK: 2029039
| Field | Detail |
|---|---|
| Company | Nasus Pharma LTD (NSRX) |
| Form Type | 6-K |
| Filed Date | Nov 18, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, drug-development, phase-2
TL;DR
Nasus Pharma just dosed the first patient in their NS002 Phase 2 trial. Big step for the drug!
AI Summary
Nasus Pharma Ltd. announced on November 18, 2025, the initiation of a Phase 2 clinical study for its drug candidate NS002. The first participant has been dosed, marking a significant step in the development of this pharmaceutical product.
Why It Matters
This milestone advances Nasus Pharma's drug development pipeline, potentially leading to a new treatment option if the Phase 2 study is successful.
Risk Assessment
Risk Level: medium — Clinical trial initiations carry inherent risks related to study outcomes, regulatory approvals, and market adoption.
Key Players & Entities
- Nasus Pharma Ltd. (company) — Filer of the 6-K report and developer of NS002
- NS002 (drug_candidate) — The drug being studied in the Phase 2 clinical trial
FAQ
What is the purpose of the Phase 2 clinical study for NS002?
The filing announces the initiation of the Phase 2 clinical study for NS002, but does not detail its specific purpose or objectives.
When was the press release announcing the study initiation issued?
The press release was issued on November 18, 2025.
What is the Commission File Number for Nasus Pharma Ltd.?
The Commission File Number for Nasus Pharma Ltd. is 001-42796.
What is the principal executive office address for Nasus Pharma Ltd.?
The principal executive office is located at Yigal Alon 65, Tel Aviv, Israel, 6744317.
What form does Nasus Pharma Ltd. file annual reports under?
Nasus Pharma Ltd. files annual reports under Form 20-F.
Filing Stats: 213 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2025-11-18 08:15:10
Filing Documents
- form6-k.htm (6-K) — 18KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-023992.txt ( ) — 38KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 (Report No. 2) Commission File Number: 001-42796 Nasus Pharma Ltd. Yigal Alon 65 Tel Aviv, Israel 6744317 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On November 18, 2025, Nasus Pharma Ltd. (the “Company”), issued a press release titled “Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K. EXHIBIT INDEX Exhibit No. Description 99.1 Press Release issued on November 18, 2025 by Nasus Pharma Ltd. titled “Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed.” SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NASUS PHARMA LTD. Date: November 18, 2025 By: /s/ Dan Teleman Name: Dan Teleman Title: Chief Executive Officer